Smart Technology Facilitated Patient-centered Venous Thromboembolism Management: A Multicenter Cohort Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Venous Thromboembolism
- Sponsor
- Navy General Hospital, Beijing
- Enrollment
- 2353
- Locations
- 1
- Primary Endpoint
- VTE-related composite event
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.
The objective of this study is to observe the long-term effect of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on thromboprophylaxis, and establish a foundation of evidence for managing patients with high-risk VTE.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inpatients ≥18 years of age at admission;
- •At high-risk of VTE at discharge: Padua score ≥4 for medical patients and Caprini score ≥5 for surgical patients;
- •Signed informed consent.
Exclusion Criteria
- •Diagnosis of VTE at discharge;
- •Mental disorder or combination of other serious diseases leading to incapacity for independent living;
- •Inability to use smartphones, computer tablets and other smart devices;
- •Being pregnant or breastfeeding;
- •Have participated in similar trials or are undergoing other clinical trials.
Outcomes
Primary Outcomes
VTE-related composite event
Time Frame: At 1-year follow-up
The primary outcome was the occurrence of VTE-related composite event at 1-year follow-up, which was defined as a composite of VTE, major bleeding, VTE-related hospitalization, and all-cause death.
Secondary Outcomes
- VTE-KAP questionnaire score(At 3, 12, and 24-month follow-up)
- Generic quality of life(At 3, 12, and 24-month follow-up)
- New-onset of atrial fibrillation or atrial flutter(At 3, 6, 12, and 24-month follow-up)
- Major bleeding(At 3, 6, 12, and 24-month follow-up)
- Death(At 3, 6, 12, and 24-month follow-up)
- VTE events(At 3, 6, 12, and 24-month follow-up)
- VTE-related hospitalization(At 3, 6, 12, and 24-month follow-up)